About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in San Francisco | 89 Studies

Clinical Trials MelanomaSan Francisco

Melanoma Clinical Trials in San Francisco

Find 89 clinical trials for melanoma near San Francisco, California. Connect with research centers in your area.

All Melanoma trials nationwide All trials in San Francisco

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 41-60 of 89 trials

RecruitingA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell…NCT06330064·Los Angeles, California and 119 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedAbexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesThis phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite…NCT03590054·San Francisco, California

CompletedStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaThis is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy…NCT01909453·Birmingham, Alabama and 281 others

Active not recruitingPhysician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryThis randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant…NCT02506153·Birmingham, Alabama and 575 others

Active not recruitingHigh-Dose Interferon Alfa in Treating Patients With Stage II or Stage III MelanomaRATIONALE: Interferon alfa may interfere with the growth of cancer cells.NCT00003641·Birmingham, Alabama and 532 others

CompletedBiochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic MelanomaA phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).NCT01743157·San Francisco, California

CompletedA Companion Study for Patients Enrolled in Prior/Parent Ipilimumab StudiesThe purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.NCT00162123·Tucson, Arizona and 57 others

TerminatedA Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerThis trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas.NCT04254107·Birmingham, Alabama and 35 others

CompletedA Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsStudy CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019).NCT05293496·Los Angeles, California and 9 others

WithdrawnA Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous MelanomaThis is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in…NCT05572463·San Francisco, California and 12 others

TerminatedRovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsThe primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid…NCT02709889·Gilbert, Arizona and 29 others

CompletedA Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic MelanomaThis open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600…NCT01271803·Los Angeles, California and 9 others

Active not recruitingA Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsTo evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability…NCT05907304·San Francisco, California and 28 others

CompletedStudy of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaThe primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in…NCT01927419·San Francisco, California and 20 others

TerminatedXmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor TherapyThis is a first-in-human, multi-center, multi-cohort, open-label, phase Ib/II study of XmAb22841 (CTLA-4 X LAG3) administered in combination with XmAb23104 (PD1 X ICOS) in…NCT05695898·San Francisco, California

Active not recruitingA Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic MelanomaThe purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic…NCT06054555·Long Beach, California and 179 others

RecruitingA Study of IBI363 in Subjects with Advanced Solid MalignanciesThis is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid…NCT06281678·San Francisco, California and 8 others

CompletedA Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)This is a Phase 1/2, open label study. Phase 1 consists of 2 parts.NCT02327078·Birmingham, Alabama and 23 others

TerminatedStudy of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) PathwayThis is a multicenter clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers.NCT06287463·Los Angeles, California and 8 others

RecruitingA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called…NCT06246916·Chandler, Arizona and 111 others

PreviousPage 3 of 5Next

Other Conditions in San Francisco

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma